KR20240093852A - 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료 - Google Patents

중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료 Download PDF

Info

Publication number
KR20240093852A
KR20240093852A KR1020247016925A KR20247016925A KR20240093852A KR 20240093852 A KR20240093852 A KR 20240093852A KR 1020247016925 A KR1020247016925 A KR 1020247016925A KR 20247016925 A KR20247016925 A KR 20247016925A KR 20240093852 A KR20240093852 A KR 20240093852A
Authority
KR
South Korea
Prior art keywords
cbd
asd
subject
abc
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016925A
Other languages
English (en)
Korean (ko)
Inventor
조셉 팔룸보
스티븐 브이 오퀸
Original Assignee
지네르바 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지네르바 파마슈티컬스, 인코포레이티드 filed Critical 지네르바 파마슈티컬스, 인코포레이티드
Publication of KR20240093852A publication Critical patent/KR20240093852A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247016925A 2021-10-22 2022-10-20 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료 Pending KR20240093852A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271015P 2021-10-22 2021-10-22
US63/271,015 2021-10-22
PCT/US2022/078449 WO2023070045A1 (en) 2021-10-22 2022-10-20 Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Publications (1)

Publication Number Publication Date
KR20240093852A true KR20240093852A (ko) 2024-06-24

Family

ID=84358575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016925A Pending KR20240093852A (ko) 2021-10-22 2022-10-20 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료

Country Status (10)

Country Link
US (1) US20240342198A1 (enExample)
EP (1) EP4419091A1 (enExample)
JP (1) JP2024536581A (enExample)
KR (1) KR20240093852A (enExample)
CN (1) CN118284412A (enExample)
AU (1) AU2022373753A1 (enExample)
CA (1) CA3235677A1 (enExample)
IL (1) IL312328A (enExample)
MX (1) MX2024004766A (enExample)
WO (1) WO2023070045A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA3300266A1 (en) * 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US20210369643A1 (en) * 2020-05-26 2021-12-02 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs

Also Published As

Publication number Publication date
JP2024536581A (ja) 2024-10-04
AU2022373753A1 (en) 2024-05-09
CN118284412A (zh) 2024-07-02
EP4419091A1 (en) 2024-08-28
IL312328A (en) 2024-06-01
WO2023070045A1 (en) 2023-04-27
US20240342198A1 (en) 2024-10-17
CA3235677A1 (en) 2023-04-27
MX2024004766A (es) 2024-06-11

Similar Documents

Publication Publication Date Title
US12226373B2 (en) Treatment of fragile X syndrome with cannabidiol
US20250213465A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
KR20200113197A (ko) 우울증 치료를 위한 에스케타민
KR20210104084A (ko) 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
US12582664B2 (en) Treatment of fragile x syndrome with cannabidiol
US20240342198A1 (en) Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance
JP7830358B2 (ja) カンナビジオールによる脆弱ｘ症候群の処置
KR20230016003A (ko) 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
US20230000793A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20230000792A1 (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
US20250177322A1 (en) Treatment of fragile x syndrome with cannabidiol

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000